- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06193200
To Evaluate the Effects of EryDex in Patients With A-T (NEAT)
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Neurological Effects of EryDex in Subjects With Ataxia Telangiectasia (NEAT)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The EryDex System (EDS) is a combination product that is used to load dexamethasone sodium phosphate (DSP) into autologous erythrocytes (EryDex) which is infused into the patient.
In the placebo arm, the subjects will receive autologous erythrocytes prepared with the EDS process using a placebo solution.
Upon completion of all screening assessments for eligibility, subjects meeting all selection criteria at baseline will be randomized in a 1:1 fashion to EryDex or placebo. Approximately 86 subjects 6- to 9-years-old, approximately 43 per group, will be randomized. Approximately 20 subjects 10 years of age and above, 10 per treatment group, may also be enrolled.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Dirk Thye, MD
- Phone Number: 415-533-3236
- Email: dthye@quincetx.com
Study Contact Backup
- Name: Irene Maccabruni, M.Sc
- Phone Number: 00393402752483
- Email: imaccabruni@quincetx.com
Study Locations
-
-
-
Leuven, Belgium, 3000
- UZ Leuven
-
Contact:
- Isabelle Meyts, MD
-
-
-
-
-
Copenhagen, Denmark, 2100
- Copenhagen University Hospital, Rigshospitalet, Department of Pediatric Neurology
-
Contact:
- Malene Landbo Børresen, MD
-
-
-
-
-
Frankfurt, Germany, 60590
- University Hospital Frankfurt, Pediatric and Adolescent Clinic
-
Contact:
- Jordis Trischler, MD
-
-
-
-
-
Brescia, Italy, 25123
- Spedali Civili di Brescia, Pediatric immunology department
-
Contact:
- Raffaele Badolato, MD
-
Rom, Italy, 00161
- Policlinico Umberto I, La sapienza University, Department of neurosciences and menthal health
-
Contact:
- Francesco Pisani, MD
-
-
-
-
-
Oslo, Norway, 0372
- Oslo University Hospital, Rikshospitalet, Division of Pediatric and Adolescent Medicine, Norwegian National Unit for Newborn Screening
-
Contact:
- Asbjørg Stray-Pedersen, MD
-
-
-
-
-
Warsaw, Poland, 04-736
- Instytut "Pomnik-Centrum Zdrowia Dziecka", Immunology clinic
-
Contact:
- Barbara Pietrucha, MD
-
-
-
-
-
Barcelona, Spain, 08035
- Hospital Universitari Vall d'Hebron, Department of pediatric neurology
-
Contact:
- David Gómez Andrés, MD
-
Madrid, Spain, 28046
- Hospital Universitario La Paz, Department of pediatric neurology
-
Contact:
- María del Mar García Romero, MD
-
-
-
-
-
London, United Kingdom, WC1N 1DZ
- Great Ormond Street Hospital for Children, Zayed Centre for Research
-
Contact:
- Winnie Ip, MD
-
Nottingham, United Kingdom, NG7 2UH
- Nottingham Children's Hospital, Queen's Medical Center, Children's neurology
-
-
-
-
California
-
Los Angeles, California, United States, 90095
- University of California Los Angeles (UCLA), Ataxia Center and HD Center of excellence
-
Contact:
- Susan L. Perlman, MD
-
-
Maryland
-
Baltimore, Maryland, United States, 21289
- The Johns Hopkins Hospital, Division of pediatric allergy and immunology
-
Contact:
- Howard M. Lederman, MD
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital, Division of neurology
-
Contact:
- Steve W. Wu, MD
-
-
Texas
-
Houston, Texas, United States, 77030
- UT Health Houston, Department of pediatrics, division of child & adolescent neurology
-
Contact:
- Sam Nicholas Russo, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Clinical diagnosis of A-T
- In autonomous gait or is helped by periodic use of a support
- Genetic confirmation of A-T
- Body weight ≥15 kg
Exclusion Criteria:
- Participation in another clinical study
- Immune impairment
- History of severe impairment of the immunological system
- Current neoplastic disease or previous neoplastic disease not in remission for at least 2 years
- Severe or unstable pulmonary disease
- Uncontrolled diabetes
- Current chronic or acute significant renal and/or hepatic impairment
- Any previous oral or parenteral steroid use within 6 weeks before Baseline. Treatment with inhaled or intranasal steroids for asthma or allergies, as well as use of topical steroids will be permitted
- A disability that may prevent the subject from completing all study requirements
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dexamethasone sodium phosphate
IV infusion of dexamethasone sodium phosphate (DSP) encapsulated in autologous erythrocytes using the EryDex System (EDS)
|
Dexamethasone sodium phosphate encapsulated in autologous erythrocytes and administered via IV infusion
Other Names:
|
Placebo Comparator: Placebo
IV infusion of placebo encapsulated in autologous erythrocytes using the EryDex System (EDS)
|
Placebo encapsulated in autologous erythrocytes and administered via IV infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rescored modified International Cooperative Ataxia Rating Scale (RmICARS)
Time Frame: Baseline to Visit 9 (approximately 6 months)
|
Change of the RmICARS from baseline to Visit 9 compared to placebo (6 to 9 years old)
|
Baseline to Visit 9 (approximately 6 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Global Impression of Severity (CGI-S)
Time Frame: Baseline to Visit 9 (approximately 6 months)
|
Change in CGI-S from baseline to Visit 9
|
Baseline to Visit 9 (approximately 6 months)
|
Clinical Global Impression of Change (CGI-C)
Time Frame: Baseline to Visit 9 (approximately 6 months)
|
Clinical Global Impression of Change (CGI-C) at Visit 9
|
Baseline to Visit 9 (approximately 6 months)
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Neurologic Manifestations
- Genetic Diseases, Inborn
- Dyskinesias
- DNA Repair-Deficiency Disorders
- Neurocutaneous Syndromes
- Cerebellar Diseases
- Primary Immunodeficiency Diseases
- Spinocerebellar Ataxias
- Ataxia
- Telangiectasis
- Cerebellar Ataxia
- Ataxia Telangiectasia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Protease Inhibitors
- Dexamethasone
- Dexamethasone acetate
- BB 1101
- Dexamethasone 21-phosphate
Other Study ID Numbers
- IEDAT-04-2022
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ataxia Telangiectasia
-
Matrix Biomed, Inc.The University of Texas Health Science Center, HoustonNot yet recruitingAtaxia Telangiectasia | Ataxia Telangiectasia Louis-Bar | Ataxia Telangiectasia in ChildrenUnited States
-
Johns Hopkins UniversityTerminatedAtaxia-Telangiectasia (A-T)United States
-
NHS TaysideUniversity of DundeeCompletedAtaxia-TelangiectasiaUnited Kingdom
-
St. Jude Children's Research HospitalNational Cancer Institute (NCI); Children's Hospital of PhiladelphiaCompletedAtaxia-TelangiectasiaUnited States
-
Institute of Child HealthGreat Ormond Street Hospital for Children NHS Foundation TrustCompletedAtaxia Telangiectasia (AT)United Kingdom
-
University of PlymouthRecruitingAtaxia Telangiectasia | Ataxia Telangiectasia in ChildrenUnited Kingdom
-
The University of QueenslandNational Health and Medical Research Council, AustraliaCompletedAtaxia TelangiectasiaAustralia
-
ErydelRecruitingAtaxia TelangiectasiaUnited States, Australia, Belgium, Germany, India, Italy, Poland, Spain, Tunisia
-
Acasti Pharma Inc.Active, not recruitingAtaxia TelangiectasiaCanada
-
University Hospital, AkershusOslo University Hospital; University Hospital of North Norway; University of... and other collaboratorsActive, not recruitingAtaxia TelangiectasiaNorway
Clinical Trials on Dexamethasone sodium phosphate
-
Christian CandrianRecruitingTotal Knee ReplacementSwitzerland
-
Ahmadu Bello University Teaching HospitalCompletedNeonatal Respiratory Distress SyndromeNigeria
-
Kenneth Taylor, M.D.TerminatedTrigger Finger DisorderUnited States
-
Laboratoires Mayoly SpindlerCompleted
-
Eyegate Pharmaceuticals, Inc.CompletedPain, Postoperative | Cataract | Anterior Chamber InflammationUnited States
-
University of Texas Southwestern Medical CenterRecruitingPhysical Inactivity | Visceral Obesity | Phosphate OverloadUnited States
-
Ottawa Hospital Research InstituteCompletedPain Syndrome | Early-stage Breast CancerCanada
-
Dr. Stephen ChoiThe Physicians' Services Incorporated FoundationCompletedShoulder Surgery | Nerve BlockCanada
-
Aciont IncNational Eye Institute (NEI)CompletedNon-Infectious Anterior UveitisUnited States